BioDelivery Sciences Reports Solid Third Quarter 2021 Results

Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year

Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow

Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opportunity of $350 - $400 million

Conference Call and Webcast Scheduled for 8:30 AM EST Today

RALEIGH, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported solid financial results for the third quarter ended September 30, 2021, including the following operational and performance highlights.

Key Business Highlights

  • Net sales of BELBUCA® and Symproic® combined grew 7.5% year-over-year. This growth was driven by record BELBUCA net sales of $36.9 million, which increased 6.3%, and Symproic net sales of $4.1 million, which increased 20%.
  • BELBUCA delivered an all-time high quarterly market share of 4.9%, despite the situation with Alvogen which was described in our 8K filing on September 21, 2021.
  • Total BELBUCA prescriptions were over 121,000 during the third quarter, a new record high and representing year-over-year prescription volume growth of 7.7%.
  • Total Symproic prescriptions were over 19,200 in the third quarter, delivering 7.6% year-over-year growth and reflecting record high TRx volume, record high NRx volume of over 11,100 leading to a record NRx share of 14.3%.
  • Continued to achieve strong profitability, delivering $6.7 million of GAAP Net Income, an attractive 27% EBITDA margin in the third quarter of 2021, GAAP EPS of $0.07, as well as generating $7.0 million in operating cash.
  • Acquisition of ELYXYB for the treatment of acute migraine closed on September 9, 2021.

“Sales of BELBUCA and Symproic remain solid as we prepare for additional revenue growth associated with the launch of ELYXYB in the first quarter of 2022. ELYXYB, with patent protection to 2036, diversifies our portfolio, takes advantage of the synergies between pain and neurology, and leverages our current commercial infrastructure to manage ELYXYB in a very efficient way,” stated Jeff Bailey, CEO of BDSI. “Moreover, we continue our business development activities for product acquisitions and licensing opportunities, especially in the Neurology space.”

Third Quarter 2021 Financial Results

Total Company Net Revenue for the third quarter of 2021 was $41.1 million, an increase of 4.2% compared to $39.4 million in the third quarter of 2020.   Net sales of BELBUCA and Symproic combined grew 7.5% year over year.

BELBUCA Net Sales for the third quarter of 2021 were $36.9 million, an increase of 6.3% compared to $34.8 million in the third quarter of 2020. Third quarter 2020 net sales were positively impacted by the gross to net channel refresh.

Symproic Net Sales for the third quarter were $4.1 million, an increase of 20% compared to $3.5 million in the third quarter of 2020.

Other Revenue for the third quarter totaled $20 thousand of royalty revenue, compared to $1.2 million in the third quarter of 2020, which included royalty revenue of approximately $0.7 million and approximately $0.6 million of Bunavail net sales.

Total Operating Expenses for the third quarter of 2021 were $25.5 million, compared to $22.5 million in the third quarter of 2020.

GAAP Net Income for the third quarter of 2021 was $6.7 million, or $0.07 per share, compared to GAAP net income of $9.4 million, or $0.09 per share, in the third quarter of 2020.

EBITDA for the third quarter of 2021 was $11.1 million, or 27% of net sales, compared to $13.4 million or 34% of net sales, in the third quarter of 2020.

Non-GAAP Net Income for the third quarter of 2021 was $10.3 million and reflects GAAP net income excluding stock-based compensation and non-cash amortization of intangible assets as compared to non-GAAP net income of $12.7 million in the third quarter of 2020, excluding the same items.

Cash Position: As of September 30, 2021, cash and cash equivalents were approximately $100.7 million, compared to $111.6 million as of December 31, 2020. The change in year-to-date cash of ($10.9) million reflects operating cash flow generation of $27.3 million, $11.9 million in share buybacks, the prepayment of $20.0 million of debt, as well as the $6.0 million upfront payment for ELYXYB and $0.4 million in transaction related costs. For the third quarter, total cash on hand decreased by $19.1 million versus June 30, 2021, with operating cash flow generation of $7.0 million being partially offset by $20.0 million used towards an early, penalty-free debt repayment of our term loan and a $6.0 million upfront payment to Dr. Reddy’s for ELYXYB, along with $0.4 million in transaction related costs. The $20.0 million pre-payment will result in approximately $4.4 million of interest savings over the course of the remaining loan period.

Financial Guidance

For 2021 financial guidance, the Company is lowering its full year 2021 total net revenue guidance range to $162 - $167 million from $170 - $180 million previously communicated. The situation with Alvogen is a factor contributing to our amended guidance. BDSI now expects BELBUCA net sales for 2021 to be in the range of $144 - $148 million dollars. The Company continues to estimate total operating expenses for the ongoing business to be in the range of $115 - $120 million, including pre-launch investments to support the first quarter 2022 launch of ELYXYB.   EBITDA for the ongoing business, excluding ELYXYB, is projected to be at the lower end of the $40 - $50 million range in 2021. Following the acquisition of ELYXYB, total EBITDA is expected to be less than $40 million in 2021 due to the Company’s investments to prepare for the first quarter 2022 launch.

“We are investing in our future by entering into the attractive acute migraine space while driving the growth of our robust pain franchise,” stated Jeff Bailey. “We expect ELYXYB to be financially accretive within 24 months after its launch, and to be a differentiated and exciting new treatment option for both prescribers and patients. Our balance sheet remains strong and we will continue to invest to grow our current products and, through the establishment of a dedicated neurology sales force, we will be able to leverage our current infrastructure to manage the addition of ELYXYB in a very efficient way.”

Conference Call & Webcast Details

BioDelivery Sciences will host a conference call and webcast today, November 3, 2021, at 8:30 a.m. ET to present third quarter 2021 results and to provide a business update.  Dial-in details are as follows:

Date:Wednesday, November 3, 2021
Time:8:30 AM Eastern Time
Conference ID:13723637


BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated pain and neurology products and leverages its experienced sales and marketing organization to educate prescribers on their unique features. BDSI's products address serious and debilitating conditions, including chronic pain, acute migraine and opioid-induced constipation.


This press release and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. (“BDSI”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to BDSI’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of BDSI’s management and are subject to significant risks and uncertainties, including those detailed in BDSI’s filings with the Securities and Exchange Commission. Actual results including, without limitation, the expectations for: net revenue, BELBUCA net sales, operating expenses, EBITDA and operating cash flows for 2021, the planned launch of ELYXYB, including net sales of ELYXYB and potential expansion opportunities for ELYXYB, may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond BDSI’s control) including the risk that the current COVID-19 pandemic impacts on our supply chain, commercial partners, patients and their physicians and the healthcare facilities in which they work, and our personnel are greater than we anticipate, as well as those set forth in our 2020 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, or GAAP, including non-GAAP net income and EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

Non-GAAP net income adjusts for one-time and non-cash charges by excluding the following from GAAP net income: stock-based compensation expense, non-cash amortization of intangible assets, and the financial impact of certain one-time items that are non-recurring, including the discontinuation of Bunavail, and costs associated with the CEO transition in Q2 2020.

EBITDA excludes net interest, including both interest expense and interest income, provision for (benefit from) income taxes, depreciation, and amortization.

The Company's management and board of directors utilize these non-GAAP financial measures to evaluate the Company's performance. The Company provides these non-GAAP measures of the Company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income and EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income and EBITDA should not be considered measures of our liquidity.

A reconciliation of certain GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

© 2021 BioDelivery Sciences International, Inc.  All rights reserved.

Bob Yedid
LifeSci Advisors


 September 30,
 December 31,
Current assets:   
Cash and cash equivalents$100,710   $111,584  
Accounts receivable, net57,572   48,150  
Inventory, net23,075   17,443  
Prepaid expenses and other current assets6,904   5,208  
Total current assets188,261   182,385  
Property and equipment, net1,525   1,418  
Goodwill2,715   2,715  
License and distribution rights, net63,569   53,376  
Total assets$256,070   $239,894  
Current liabilities:   
Accounts payable and accrued liabilities$74,580   $52,995  
Notes payable, current3,077     
Total current liabilities77,657   52,995  
Notes payable, less current maturities55,638   78,452  
Other long-term liabilities   213  
Total liabilities133,295   131,660  
Commitments and contingencies   
Stockholders’ equity:   
Preferred Stock, 5,000,000 shares authorized; Series B Non-Voting Convertible Preferred Stock, $0.001 par value, 443 shares outstanding at September 30, 2021 and December 31, 2020, respectively.     
Common Stock, $0.001 par value; 235,000,000 shares authorized at September 30, 2021 and December 31, 2020, respectively; 102,057,290 and 101,417,441 shares issued; 98,791,606 and 101,354,447 shares outstanding at September 30, 2021 and December 31, 2020, respectively.104   104  
Additional paid-in capital454,738   449,264  
Treasury stock, at cost, 3,265,684 and 62,994 shares, as of September 30, 2021 and December 31, 2020, respectively.(12,155)  (252) 
Accumulated deficit(319,912)  (340,882) 
Total stockholders’ equity122,775   108,234  
Total liabilities and stockholders’ equity$256,070   $239,894  



 Three months ended September 30, Nine months ended September 30,
 2021 2020 2021 2020
Product sales$41,072   $38,785   $122,398   $112,946  
Product royalty revenues20   658   1,151   1,358  
Total Revenues:41,092   39,443   123,549   114,304  
Cost of sales6,365   5,376   16,470   16,371  
Selling, general and administrative25,468   22,461   79,007   77,408  
Total Expenses:25,468   22,461   79,007   77,408  
Income from operations9,259   11,606   28,072   20,525  
Interest expense, net(1,984)  (2,010)  (5,962)  (4,997) 
Other (expense)/income, net   (2)  (1)  6  
Income before income taxes$7,275   $9,594   $22,109   $15,534  
Income tax provision(606)  (211)  (1,139)  (19) 
Net income attributable to common stockholders$6,669   $9,383   $20,970   $15,515  
Weighted average common stock shares outstanding98,699,857   101,031,317   99,485,399   99,377,748  
Basic earnings per share$0.07   $0.09   $0.21   $0.16  
Weighted average common stock shares outstanding102,430,883   105,783,568   103,473,967   104,836,493  
Diluted earnings per share$0.07   $0.09   $0.20   $0.15  



 Nine months ended September 30,
 2021 2020
Operating activities:   
Net income$20,970    $15,515   
Adjustments to reconcile net income to net cash flows from operating activities   
Depreciation and amortization97   467  
Accretion of debt discount and loan costs264   231  
Amortization of intangible assets5,262   5,248  
Provision for/(release of) inventory obsolescence1,100   (297) 
Stock-based compensation expense5,024   7,845  
Net change in operating lease assets and liabilities(30)    
Changes in assets and liabilities:   
Accounts receivable(9,422)  (5,040) 
Inventories(6,731)  (7,278) 
Prepaid expenses and other assets(1,856)  (1,985) 
Accounts payable and accrued liabilities12,005   (701) 
Taxes payable606   (40) 
Net cash flows provided by operating activities27,289   13,965  
Investing activities:   
Product acquisitions(6,456)    
Acquisitions of property, plant and equipment(415)    
Net cash flows used in investing activities(6,871)    
Financing activities:   
Payment on notes payable(20,000)    
Proceeds from notes payable   20,000  
Proceeds from exercise of stock options611   2,761  
Payment on share repurchase(11,903)    
Payment on deferred financing fees   (437) 
Net cash flows (used in)/provided by financing activities(31,292)  22,324  
Net change in cash and cash equivalents(10,874)  36,289  
Cash and cash equivalents at beginning of period111,584   63,888  
Cash and cash equivalents at end of period$100,710   $100,177  



  Three Months Ended
September 30,
 Nine Months Ended
September 30,
Reconciliation of GAAP net income to EBITDA (non-GAAP)   2021 2020  2021 2020
GAAP net income $6,669  $9,383   $20,970  $15,515  
Add back/(subtract):      
Income tax provision  606   211    1,139   19  
Net interest expense  1,984   2,012    5,962   4,991  
Depreciation and amortization  1,837   1,754    5,359   5,715  
EBITDA $11,096  $13,360   $33,430  $26,240  
Reconciliation of GAAP net income to Non-GAAP net income      
GAAP net income $6,669
  $ 9,383   $20,970
Non-GAAP adjustments:      
Stock-based compensation expense  1,837   1,473    5,024   4,424  
Amortization of intangible assets  1,795   1,734    5,262   5,248  
Non-recurring financial impact of CEO transition     67       5,078  
Non-recurring financial impact of BUNAVAIL discontinuation            295  
Non-GAAP net income $10,301  $12,657   $31,256  $30,560